Latest Breaking News On - Sab biotherapeutics inc - Page 2 : vimarsana.com

EXCLUSIVE: SAB Biotherapeutics Kickstarts Phase 1 Study For Its Lead Type 1 Diabetes Hopeful In Australia

SAB Biotherapeutics Inc (NASDAQ: SABS) announced that the first HUMAN trial participants (Fully HUman anti-thymocyte biologic in a first-in-MAN clinical study) have been dosed in Australia. This Phase 1 randomized, double-blind, placebo-controlled, single-ascending dose, adaptive design clinical study was designed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous SAB-142 in healthy volunteers and participants with type-1 diabetes (T1D). SAB-142 is a first-

SAB Biotherapeutics (SABS) Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142

SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Update

SAB Biotherapeutics, Inc. (NASDAQ:SABS – Get Free Report) saw a significant drop in short interest in the month of September. As of September 15th, there was short interest totalling 306,500 shares, a drop of 17.5% from the August 31st total of 371,600 shares. Based on an average daily volume of 35,900 shares, the short-interest ratio […]

SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Down 17.5% in September

SAB Biotherapeutics, Inc. (NASDAQ:SABS – Get Free Report) saw a large decrease in short interest in September. As of September 15th, there was short interest totalling 306,500 shares, a decrease of 17.5% from the August 31st total of 371,600 shares. Based on an average daily volume of 35,900 shares, the short-interest ratio is presently 8.5 […]

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Sees Significant Growth in Short Interest